DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/456zzs/investigation) has announced the addition of the "Investigation Report on China Olmesartan Market, 2010-2019" report to their offering.
In 1991, olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd and was patented in many countries. In Apr. 2002, olmesartan medoxomil was approved by FDA to enter the American market in May. It has now become the best- selling drug in the world after it succeeded in the US market.
Compared with other ARBs, olmesartan medoxomil has distinctive pharmacokinetic properties. It develops fast after entering China with annual sales rising from CNY 4448 in 2010 to CNY 99.07 million and CAGR reaching up to 204.15%. Currently, there are three manufacturers of olmesartan in Chinese market: Shanghai Sankyo Pharmaceuticals Co., Ltd, Shanghai Sine Promod Pharmaceutical Co., Ltd and Beijing Winsunny Pharmaceutical Co., Ltd, among which Shanghai Sankyo Pharmaceuticals Co., Ltd has the biggest market share of 94.45% in 2014 with sales value reaching up to CNY 93.57 million in the same year.
With the increase of the incidence of cardiovascular disease and its number of cases, the market size of olmesartan is estimated to keep expanding in the next few years.
Key Topics Covered:
1 Related Concepts of Olmesartan
2 Market Profile of Olmesartan in China
3 Survey on Sales Status of Olmesartan in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Olmesartan in China, 2010-2014
5 Survey on Dosage Forms of Olmesartan in China, 2010-2014
6 Reference Price of Olmesartan in Chinese Hospitals in 2014
7 Major Manufacturers of Olmesartan in Chinese Market, 2010-2014
8 Market Outlook of Olmesartan in China, 2015-2019
- Beijing Winsunny Pharmaceutical Co., Ltd
- Shanghai Sankyo Pharmaceuticals Co., Ltd
- Shanghai Sine Promod Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/456zzs/investigation